Population pharmacokinetic modelling is widely used within the field of clinical pharmacology as it helps to define the sources and correlates of pharmacokinetic variability in target patient populations and their impact upon drug disposition. This review focuses on the fundamentals of population pharmacokinetic modelling and provides an overview of the commonly available software programs that perform these functions.
This review attempts to define the common, fundamental aspects of population pharmacokinetic modelling through a discussion of the literature describing the techniques and placing them in the appropriate context. An overview of the most commonly available software programs is also provided.
Population pharmacokinetic modelling is a powerful approach where sources and correlates of pharmacokinetic variability can be identified in a target patient population receiving a pharmacological agent. There is a need to further standardize and establish the best approaches in modelling so that any model created can be systematically evaluated and the results relied upon. Various nonlinear mixed-effects modelling methods, packaged in a variety of software programs, are available today. When selecting population pharmacokinetic software programs, the consumer needs to consider several factors, including usability (e.g. user interface, native platform, price, input and output specificity, as well as intuitiveness), content (e.g. algorithms and data output) and support (e.g. technical and clinical).
Pharmacokinetic Parameter Population Pharmacokinetic Modelling Pharmacokinetic Variability Population Pharmacokinetic Study Target Patient Population
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
No sources of funding were used to assist in the preparation of this review. The authors have no potential conflicts of interest that are directly relevant to the content of this review to declare.
Jelliffe RW, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380–93CrossRefPubMedGoogle Scholar
Jelliffe RW, Gomis P, Schumitzky A. A population model of gentamicin made with a new nonparametric EM algorithm. Los Angeles (CA): Laboratory of Applied Pharmacokinetics, USC School of Medicine, 1990. Technical report no.: 90–4Google Scholar
Concordet D, Léger F, Ané C. Population PK/PD analysis. In: Chow S, editor. Encyclopedia of biopharmaceutical statistics. New York: Marcel Dekker, Inc., 2004Google Scholar
Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 2006; 45: 365–83CrossRefPubMedGoogle Scholar
Jelliffe R, Schumitzky A, Van Guilder M. Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods. Ther Drug Monit 2000; 22: 354–65CrossRefPubMedGoogle Scholar
Ogungbenro K, Aarons L. Design of population pharmacokinetic experiments using prior information. Xenobiotica 2007; 37: 1311–30CrossRefPubMedGoogle Scholar
Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231–43CrossRefPubMedGoogle Scholar
Dartois C, Brendel K, Comets E, et al. Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey. Br J Clin Pharmacol 2007; 64: 603–12CrossRefPubMedPubMedCentralGoogle Scholar
Pillai GC, Mentre F, Steimer JL. Non-linear mixed effects modeling-from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 2005; 32: 161–83CrossRefPubMedGoogle Scholar
Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60–83CrossRefPubMedPubMedCentralGoogle Scholar
Machado SG, Miller R, Hu C. A regulatory perspective on pharmacokinetic/pharmacodynamic modelling. Stat Methods Med Res 1999; 8: 217–45CrossRefPubMedGoogle Scholar
Aarons L, Balant LP, Mentre F, et al. Population approaches in drug development: report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur J Clin Pharmacol 1994; 46: 389–91CrossRefPubMedGoogle Scholar
Buffington DE, Lampasona V, Chandler MH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet 1993; 25: 205–16CrossRefPubMedGoogle Scholar
Charles BG, Duffull SB. Pharmacokinetic software for the health sciences: choosing the right package for teaching purposes. Clin Pharmacokinet 2001; 40: 395–403CrossRefPubMedGoogle Scholar
Dartois C, Lemenuel-Diot A, Laveille C, et al. Evaluation of uncertainty parameters estimated by different population PK software and methods. J Pharmacokinet Pharmacodyn 2007; 34: 289–311CrossRefPubMedGoogle Scholar